The news of Barclays maintaining an Equal-Weight rating on Cardinal Health and raising the price target from $80 to $85 is directly related to the company. However, as the rating remains unchanged, the short-term impact on the stock price is expected to be neutral. The increased price target may have a positive influence, but it is not significant enough to change the overall short-term outlook.